137 results about "Co medication" patented technology

The invention provides application of an SRC inhibitor combined with a KRAS-G12C inhibitor to preparation of a medicine for treating KRAS-G12C mutant lung cancer and a medicine composition, and relates to the technical field of biological medicine, compared with independent use of the KRAS-G12C inhibitor, the scheme of the SRC inhibitor combined with the KRAS-G12C inhibitor can effectively inhibit proliferation and survival of KRAS-G12C mutant lung cancer cells, and the application of the SRC inhibitor combined with the KRAS-G12C inhibitor to preparation of the medicine for treating the KRAS-G12C mutant lung cancer can be used for preparing the medicine for treating the KRAS-G12C mutant lung cancer. The compound can effectively inhibit the activation of a KRAS-MARK pathway and an SRC-FAK pathway, the combination of the compound and the compound has a synergistic anti-tumor effect, and the compound and the compound can be directly combined for medication, can also be prepared into a combined preparation for treating KRAS mutant lung cancer, and have a good clinical transformation prospect.

The invention relates to application of a combined pharmaceutical composition in preparation of a medicine for resisting transforming follicular lymphoma. Active components in the combined pharmaceutical composition comprise a first component and a second component, the first component is selected from any one or a combination of at least two of sitagliflozin, pharmaceutically acceptable salt, isomer, solvate and metabolite of sitagliflozin; and the second component is selected from any one or a combination of at least two of chidamide, pharmaceutically acceptable salts, isomers, solvates and metabolites of the chidamide. Research finds that the combined use of the two active components not only can reduce the dosage of each drug and improve the medication safety, but also has the effect of improving or treating convertible follicular lymphoma more remarkably than that of a single drug active component, and plays a role in synergistic promotion. The invention provides an effective drug combination strategy for improvement or treatment of convertible follicular lymphoma, and has very significant significance.

The invention provides a whole-process targeting polypeptide, a drug compound thereof, a drug delivery system and application of the whole-process targeting polypeptide. The whole-process targeting polypeptide comprises pHA and VAP which are covalently connected through a bridging structure; the VAP is LVAP, a reverse sequence polypeptide of the LVAP, DVAP or SVAP; wherein the amino acid sequence of the LVAP is as shown in SEQ ID NO: 1; the SVAP is a D-configuration polypeptide of the LVAP; the DVAP is a D-configuration polypeptide of the LVAP inverted sequence polypeptide; the bridging structure is amino-monoethylene glycol-carboxylic acid or a derivative thereof. The whole-process targeting polypeptide not only can cross a blood-brain barrier, target tumor neovascularization, cross a blood-tumor barrier, target tumor mimicry vessels, tumor cells and stem cells thereof, but also has better tumor cell affinity, anti-tumor treatment and in-vivo safety effects. Meanwhile, the drug compound or the drug delivery system has a synergistic effect after being combined with a chemotherapeutic drug, and the anti-tumor drug effect can be remarkably improved.

The invention belongs to the technical field of medicines, and provides application of Nintedanib and a plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine in preparation of a medicine for treating pulmonary fibrosis, the Nintedanib and the plant-derived cyclic peptide and radix pseudostellariae cyclic peptide B combined medicine can play a synergistic effect, and the inhibition effect on the pulmonary fibrosis process is remarkably improved. The toxic and side effects of diarrhea and intestinal mucosa injury caused by nintedanib are reduced, and a good choice is provided for clinical treatment of pulmonary fibrosis.

The invention provides application of osimertinib and saquinavir in preparation of a medicine for treating EGFR-TKI drug-resistant non-small cell lung cancer, and belongs to the technical field of biological medicine. According to the invention, osimertinib and saquinavir are combined for medication, the inhibition rate of EGFR-TKI resistant non-small cell lung cancer is obviously higher than that of single medication, the combined medication of osimertinib and saquinavir has a synergistic inhibition effect, and the inhibition efficiency is higher than that of osimertinib and rimonabant. The experimental result of the invention provides a theoretical basis for clinical drug combination of osimertinib and saquinavir and an effective scheme of NSCLC for treating EGFR-TKI drug resistance, and has a wide application prospect in the field of medicine and pharmacology.

The invention discloses a method for determining drug combination, which comprises the following steps: constructing a calculation model, and constructing the calculation model according to a response surface method; obtaining a reaction value, and inputting the reaction value to the calculation model, the reaction value including a factor main effect and a multi-factor interaction effect; a regression algorithm adapted to the relationship between the reaction variable and the reaction value; the optimal solution of the drug combination is obtained, the obtaining mode of the optimal solution is obtained from the regression algorithm, and the method further comprises a corresponding device and a storage medium. The method has the advantages that the calculation model for drug combination is constructed through the response surface method, the optimal solution of drug combination is obtained through calculation by inputting the factors, and compared with an exhaustion mode in the prior art, the efficiency is higher, and more time, manpower and resource consumption are saved.

A drug combination of purinostat mesylate and an analog thereof for preventing and treating multiple myeloma, and the use thereof. Specifically, provided is a three-drug or four-drug combination of purinostat mesylate and an analog thereof, dexamethasone and other drug, which drug combination has significantly enhanced synergistic anti-tumor activity in vitro and in vivo, synergistically inhibits the expression of the key survival protein in multiple myeloma, is superior to existing clinical combination regimens, and has no significant toxic side effects. In addition, the drug combination significantly down-regulates the expression of CDK6, and overcomes the drug resistance to an immunomodulator. In particular, the three-drug combination of puisostat mesylate, a glucocorticoid and an immunomodulator has an excellent prevention and treatment effect on multiple myeloma, especially relapsed / refractory multiple myeloma.

Purinostat mesylate (PM) for preventing and treating diffuse large B-cell lymphoma (DLBCL), an analogue thereof, a drug for combined use, and the use. PM exhibits excellent in-vivo and in-vitro anti-tumor therapeutic effects on DLBCL (DEL and DHL) subtypes with poor prognosis, DLBCL subtypes having TP53 deletion and mutation combined with a plurality of poor prognosis gene mutations, and DLBCL having TP53 mutation with double expressors, which are superior to that of most existing DLBCL clinical therapy plans. A doublet or triplet therapy of PM with rituximab, R-CHOP, venetoclax and R-CHP also exhibits excellent in-vivo therapeutic effects against DLBCL and a plurality of subtypes. Thus, PM and the drug for combined use have an important clinical significance for the DLBCL and a plurality of subtypes.

The present application relates to a pharmaceutical combination of a PARP7 inhibitor combined medication, and a use thereof in treating tumors. The pharmaceutical combination comprises: a first active ingredient PARP7 inhibitor, a second active ingredient CTLA-4 inhibitor or platinum complex, and optionally a third active ingredient PD-1 inhibitor or PD-L1 inhibitor.

The invention discloses a drug response prediction model for drug combination based on multi-omics data and transfer learning and application, belongs to the technical field of drug response prediction, and solves the problems that a traditional method is lack of a drug response prediction system based on dosage, is mostly based on single drug response prediction, is lack of modeling ability for drug combination, and cannot predict drug response. Meanwhile, the cost is high, the period is long, and individual differences cannot be reflected. According to the prediction model, digital characteristic data, drug dosage and cell line multi-omics data of drugs are integrated, the prediction model adopts a combined transfer learning algorithm, parameters of a single drug response model are migrated into a drug combination model, a gene function module is introduced to enhance the interpretability of the model, and the prediction model can be applied to drug combination. Four cross validation strategies are adopted for evaluation of the prediction model, so that the drug response of drug combination of different candidate drugs is predicted, the method can be used for predicting the response of the drug combination, and the optimal drug combination and dosage are recommended.

The invention discloses an application of a G quadruplex ligand and entecavir combined drug in resisting HBV (hepatitis B virus) infection, and relates to the technical field of HBV treatment drugs. The invention determines that a G quadruplex sequence and a G quadruplex structure exist in an HBV genome, G quadruplex ligands TMPyP4 and BRACO19 can be combined with the HBV G quadruplex structure and inhibit transcription and translation of HBV, and TMPyP4 and existing clinical drug ETV combined medication have obvious synergistic effect, which indicates that the HBV G quadruplex can be used as a new drug target for resisting virus infection. The results of the invention can provide new tools and ideas for clinical prevention and treatment of hepatitis B, especially have broad prospects in the aspects of development, clinical application and the like of anti-hepatitis B drugs and vaccines, and can also be directly applied to the field of scientific research or guide the development of inhibitors for inhibiting HBV life cycle. The invention has important application value for obtaining new anti-HBV drug targets and screening new drugs.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

The present invention relates to a method or use for treating a solid tumor with the combined administration of a TROP2-targeting antibody-drug conjugate and a PD-1 antagonist.

The use of a combination of a pyrido[2,3-d]pyrimidin-2(1H)-one derivative and an anti-PD-1 or anti-PD-L1 antibody and / or a chemotherapeutic drug in the preparation of a drug for preventing or treating a tumor disease.

The invention provides an application of combination of indobufen and butylphthalide in preparation of a drug for preventing and / or treating cerebrovascular diseases, indobufen and butylphthalide are combined for use, have a synergistic effect, remarkably improve the treatment effect, can be used for preparing the drug for preventing, secondarily preventing or treating the cerebrovascular diseases, and has a wide application prospect. The medicine is especially suitable for treating cerebral apoplexy and transient ischemic attack, and can be used for prophylactically improving cerebral infarction caused by cerebral arterial thrombosis.

This invention discloses the application of integrin αv inhibitors combined with γ-secretase inhibitors in the preparation of drugs for treating tumors. The study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors in tumor treatment exhibits a synergistic effect, not only inhibiting in situ tumor growth but also significantly suppressing tumor invasion, distant metastasis, and other malignant progression, thus helping to slow tumor progression, improve treatment efficacy, and enhance patient prognosis. Furthermore, the study found that the combined use of integrin αv inhibitors and γ-secretase inhibitors can reduce the production of the intracellular free domain of integrin αv and inhibit the activation of the classical downstream pathway of integrin αv. The combined use of integrin αv inhibitors and γ-secretase inhibitors shows broad application prospects in tumor treatment.

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition containing zolpidem tartrate and trazodone hydrochloride as well as a preparation and application of the composition, the trazodone hydrochloride can treat sleep disorders under the condition of single use and can remarkably treat the sleep disorders when being combined with zolpidem tartrate, and pharmacological experiments find that the trazodone hydrochloride can be used for treating the sleep disorders. The sleep latency can be remarkably shortened and the sleep time can be prolonged by combined medication; the content of 5HT and NE in blood is improved.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

The present invention relates to the biological field. Further, the present invention provides the use of iPSC induced differentiation into pancreatic progenitor cells combined with medication for the treatment of diabetes. Specifically, the present invention provides a monoclonal antibody that specifically inhibits the activity of BMP4, which can inhibit the differentiation of iPSC cells into common osteoblasts and adipocytes by inhibiting the activity of BMP4 protein, thereby promoting the transformation of iPSC into pancreatic progenitor cells and differentiation into islet-like cells. After the islet-like cells and ginsenoside Rb3 are combined to prepare a drug kit, the effect of lowering blood sugar can be significantly improved, and it has a good prospect for drug application.

The invention relates to a combined application of a benzimidazole compound and a BCR-ABL1TKI inhibitor in preparation of a medicine for treating leukemia related diseases, and provides a combined application of the benzimidazole compound and the BCR-ABL1TKI inhibitor in preparation of a medicine for preventing or treating leukemia related diseases.

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.

The invention provides a personalized prediction system for the clinical curative effect of a phlegm-heat clearing injection. The personalized prediction system comprises an input module, a curative effect prediction module and an output module. The input module is used for acquiring the basic condition of a to-be-predicted patient, the combined medication information and the injection time of the phlegm-heat clearing injection; the curative effect prediction module is used for predicting the ideal probability value of the clinical curative effect of a to-be-predicted patient under different combined medication treatment schemes by using the established personalized prediction model for the clinical curative effect of the phlegm-heat clearing injection by taking the C-reactive protein as an outcome index; and the output module is used for outputting probability values of ideal clinical curative effects of the to-be-predicted patient under different combined medication treatment schemes. Based on the screened 13 indexes, the XGBoost model is adopted to construct the personalized prediction model and the prediction system for the clinical curative effect of the phlegm-heat clearing injection, and the optimal personalized treatment scheme of the phlegm-heat clearing injection and the combined drug thereof is rapidly, accurately and efficiently determined.

The invention provides an application of combination of IL-28A and Anti-PD-1 antibodies in preparation of colon cancer drugs, and belongs to the technical field of biological medicines. The invention provides an application of IL-28A in preparation of an Anti-PD-1 antibody immune checkpoint sensitizer, and provides an application of combination of the IL-28A and an Anti-PD-1 antibody in preparation of a medicine for treating colon cancer. Through an intraperitoneal injection method, the result shows that the tumor can be gradually reduced and finally disappears when the IL-28A and the Anti-PD-1 are combined for treating the subcutaneous MC38 tumor of a mouse, and a remarkable synergistic effect can be generated when the IL-28A and the Anti-PD-1 antibody are combined for medication, so that the regression of the colon cancer tumor is facilitated.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to application of matrine combined with medroxyprogesterone acetate in preparation of antitumor drugs. According to the invention, matrine and medroxyprogesterone are combined for use, and the matrine and medroxyprogesterone are used for developing products such as drugs, preparations, kits and the like for treating endometrial cancer. Experimental results prove that after sophocarpidine and medroxyprogesterone acetate are combined for medication, the composition shows relatively strong activity of inhibiting endometrial cancer and relatively good synergistic inhibition effect, so that the composition has relatively good practical application value. Experimental results prove that the dosages of the two can be remarkably reduced after drug combination, and the anti-tumor effect is remarkably improved. Animal experiments show that in-vivo anti-tumor effects of sophocarpidine and medroxyprogesterone acetate can be improved by combined medication compared with that of single medication. In conclusion, the combined medication of the matrine and the medroxyprogesterone can become a new method for treating endometrial cancer patients.

The invention belongs to the field of biological medicine, and particularly relates to application of TPRA1 in the anti-tumor effect of oncolytic viruses. The invention provides the application of the oncolytic virus in preparation of the TPRA1 high-expression tumor medicine and the application of the TPRA1 accelerant in preparation of the oncolytic virus anti-tumor synergist or the drug resistance reversal agent for the first time. On the basis, the application of a substance for detecting the TPRA1 in preparation of products for oncolytic virus anti-tumor curative effect evaluation, oncolytic virus anti-tumor prognosis evaluation, tumor treatment scheme selection and / or tumor diagnosis or prognosis evaluation is provided for the first time; meanwhile, it is proved that the antitumor effect can be remarkably improved through combined medication of the oncolytic virus and the TPRA1 accelerant.

This invention provides a monoclonal antibody 4D5 against Rv0340 that can improve drug resistance in Mycobacterium tuberculosis. The heavy chain variable region of antibody 4D5 has the following amino acid sequences: CDR-H1 (SEQ ID No. 1), CDR-H2 (SEQ ID No. 2), and CDR-H3 (SEQ ID No. 3); and the light chain variable region of anti-Rv0340 monoclonal antibody 4D5 has the following amino acid sequences: CDR-L1 (SEQ ID No. 4), CDR-L2 (SEQ ID No. 5), and CDR-L3 (SEQ ID No. 6). This anti-Rv0340 monoclonal antibody 4D5 was prepared using Rv0340 protein as an antigen, and the effect of the anti-Rv0340 monoclonal antibody on the in vitro growth of Mtb in the presence of anti-tuberculosis drugs was investigated. The results showed that antibody 4D5 could significantly increase the sensitivity of Mtb to isoniazid; and when antibody 4D5 was used in combination with isoniazid, the survival rate of Mtb decreased by 26.58%. This invention provides a new monoclonal antibody drug for specifically improving the sensitivity of Mtb to isoniazid, and has the prospect of application as a monoclonal antibody drug to improve the drug resistance of Mycobacterium tuberculosis.

The invention provides a combined pharmaceutical composition of a CDK8 / 19 inhibitor and azacitidine and application of the combined pharmaceutical composition in preparation of antitumor drugs. Particularly, the compound shown in the formula (B) and azacitidine are combined for use, so that a relatively good synergistic effect is shown in a cell proliferation inhibition experiment and an in-vivo tumor model. # imgabs0 #

The invention relates to a drug combination of annona squamosa lactone compounds and sorafenib (SF), which is characterized in that four common human hepatoma cell lines HepG2, HuH7, MHCC97H and HCCLM3 are used as research objects, and the drug combination effect among different components is evaluated by using an MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide) method and Synergy Finder software. The combination of the compound and SF shows an obvious synergistic inhibition effect on the growth of hepatoma carcinoma cells, and meanwhile, the pharmaceutical composition can synergistically reduce the ATP level of the hepatoma carcinoma cells and induce hepatoma carcinoma cell apoptosis. Pharmacodynamic experiments show that the compounds annonacin and SF can synergistically inhibit tumor growth and induce tumor cell apoptosis, and have no obvious toxicity to normal organs of nude mice at a low dosage. In addition, transcriptome analysis predicts that the anti-liver cancer target of the annonacin is possibly related to the SLC33A1 gene. The method can be used for preparing anti-hepatoma drugs and researching related mechanisms. The annona lactone compound disclosed by the invention is derived from annona montana Macf. Which is an annona plant, namely annona montana Macf.

The application provides a combined medicine containing a nitrothiazolyl acid amide derivative and application thereof, and belongs to the field of chemical medicines. The combined medicine contains component A and component B which are administered simultaneously or separately and have the same or different specifications, and a pharmaceutically acceptable carrier. The component A is a nitrothiazolyl acid amide derivative shown in formula I, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The component B is a fatty acid, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The combined medicine is used for preventing and / or treating infections and related diseases. The combined medicine can produce a synergistic effect, is used for treating viral, bacterial and parasitic infections and related diseases, and has a good treatment effect. Meanwhile, the combined medicine has good safety in use, provides a new choice for clinically treating infections and related diseases caused by infections, and has a good application prospect.